Osteosarcoma metastatic – Diagnostics – Overview of Information and Clinical Research

Metastatic osteosarcoma is bone cancer that has spread from its original location to other parts of the body, most commonly the lungs. Identifying this spread early requires careful medical testing, and understanding when to seek evaluation can make a critical difference in how patients and their families prepare for what lies ahead.

Introduction: Who Should Undergo Diagnostics and When

If you or someone you care about has been diagnosed with osteosarcoma, or if there are concerns that bone cancer may have spread, knowing when to seek diagnostic testing is essential. Metastatic osteosarcoma means that cancer cells have traveled from the original bone tumor to other areas of the body. This happens in roughly one-fourth of all osteosarcoma cases, either at the time of initial diagnosis or later during or after treatment.^[1]^[13]

Anyone who has already been treated for osteosarcoma should remain watchful for new symptoms. These might include ongoing bone pain in a different location than the original tumor, unexplained breathing difficulties, persistent cough, or a sudden fracture without significant injury. Such signs may indicate that cancer has spread, often to the lungs or to other bones.^[4]^[6] Even without obvious symptoms, patients who have completed treatment need regular follow-up scans, because metastases can develop silently.

Teenagers and young adults are the most commonly affected age group, with osteosarcoma typically appearing during growth spurts. However, metastatic disease does not discriminate by age. The first peak occurs between ages 15 and 19, but a second, smaller peak appears in older adults.^[1]^[4] For patients initially diagnosed with localized osteosarcoma, ongoing monitoring is standard practice because more than half of those treated with surgery alone historically developed metastases within six months.^[23]

It is also important for newly diagnosed patients to undergo full diagnostic evaluation before any treatment begins. Approximately 20% of osteosarcoma patients already have detectable metastases at the time they first learn they have cancer.^[9]^[13] Catching this early allows doctors to plan the most appropriate combination of surgery, chemotherapy, and other treatments.

⚠️ Important

Metastatic osteosarcoma can develop months or even years after the primary tumor has been treated. Regular follow-up appointments and imaging tests are not optional—they are a critical part of survivorship care. If you notice new pain, swelling, breathing trouble, or any unexplained symptom, contact your medical team immediately rather than waiting for your next scheduled visit.

Diagnostic Methods

Diagnosing metastatic osteosarcoma involves a combination of imaging tests, laboratory work, and sometimes tissue sampling. The goal is to determine whether cancer cells have moved beyond the original bone tumor and, if so, where they have settled. Each test provides a different piece of the puzzle, and doctors often use several methods together to get the fullest picture.

Imaging Studies

Imaging is the backbone of diagnosing metastatic osteosarcoma. These tests create pictures of the inside of your body, allowing doctors to see tumors, assess their size, and check whether they have spread. The most common imaging tests include computed tomography, also called a CT scan, which uses X-rays and computers to produce detailed cross-sectional images. CT scans of the chest are particularly important because the lungs are the most common site where osteosarcoma spreads.^[7]^[23]

Magnetic resonance imaging, or MRI, uses powerful magnets and radio waves to create highly detailed images of soft tissues and bones. MRI is especially useful for examining the primary tumor area and checking whether cancer has spread to nearby tissues or other bones. It can show details that X-rays or CT scans might miss, such as the extent of tumor involvement in muscles, nerves, or blood vessels.^[7]^[11]

A bone scan, also known as total-body bone scanning or skeletal scintigraphy, involves injecting a small amount of radioactive material into a vein. This substance collects in areas of bone where cancer may be present, and a special camera detects the radiation to create images. Bone scans help identify metastases in bones throughout the body, not just near the original tumor.^[11]^[23]

Plain X-rays remain useful, particularly for the initial evaluation of bone pain or suspected fractures. They can show changes in bone structure caused by cancer, though they are less detailed than CT or MRI. Chest X-rays may be performed, but CT scans are more sensitive for detecting small lung metastases.^[7]^[11]

Positron emission tomography, or PET scan, is another imaging technique that uses a radioactive sugar injected into the bloodstream. Cancer cells, which use more sugar than normal cells, light up on the scan. PET scans are sometimes combined with CT scans (PET-CT) to provide both metabolic and structural information about tumors and potential metastases.^[7]

Biopsy Procedures

While imaging tests can suggest the presence of metastatic disease, a biopsy—removing a small sample of tissue for examination under a microscope—is often needed to confirm that a suspicious spot is indeed osteosarcoma and not another condition. Biopsies can be performed using a needle inserted through the skin (core needle biopsy) or through a small surgical incision (open biopsy).^[7]^[23]

For lung metastases, if surgical removal is planned, doctors may wait until surgery to confirm the diagnosis by examining the removed tissue. In other cases, a needle biopsy of a lung nodule may be done beforehand. The biopsy helps distinguish osteosarcoma from other cancers or benign conditions that might appear similar on scans.

Blood Tests and Other Laboratory Work

Blood tests do not diagnose metastatic osteosarcoma directly, but they provide important information about a patient’s overall health and can sometimes offer clues about disease activity. Elevated levels of certain substances, such as alkaline phosphatase or lactate dehydrogenase, may be associated with osteosarcoma, though these are not specific enough to confirm metastasis on their own.^[7]

Blood tests also help monitor organ function, especially the kidneys and liver, which can be affected by cancer or its treatment. Before starting or continuing chemotherapy, doctors check blood cell counts to ensure the body can tolerate treatment. While these tests do not show where cancer has spread, they are an essential part of the full diagnostic workup.

Physical Examination

A thorough physical exam allows doctors to look for signs of metastatic disease, such as lumps, swelling, or tenderness in bones or soft tissues. They will check how well joints move and assess whether there is pain when pressing on certain areas. A physical exam also includes listening to the lungs and heart, checking for fluid buildup or abnormal sounds that might suggest lung involvement.^[6]^[7]

Doctors will ask detailed questions about symptoms, including when they started, how severe they are, and whether anything makes them better or worse. This conversation helps guide which tests to order and how urgently they need to be done.

⚠️ Important

Before undergoing any biopsy, it is essential that complete tumor staging has been completed using imaging tests. The biopsy should ideally be performed by the same surgical team that will later remove the tumor, as improper biopsy technique can complicate later surgery and potentially worsen outcomes. Always ensure your care is coordinated among specialists experienced in treating osteosarcoma.

Diagnostics for Clinical Trial Qualification

Clinical trials are research studies that test new treatments or combinations of treatments to find better ways to manage metastatic osteosarcoma. Participating in a clinical trial may offer access to cutting-edge therapies not yet widely available. However, enrolling in a trial requires meeting specific eligibility criteria, which are determined through diagnostic testing.

Most clinical trials for metastatic osteosarcoma require confirmation that the disease has indeed spread. This is typically done through imaging studies such as chest CT scans to detect lung metastases or bone scans to identify bone metastases. Trials may specify exactly how recent these scans must be—often within a few weeks of enrollment—to ensure the most current information about disease status.^[10]

A biopsy confirming the diagnosis of osteosarcoma is usually required for trial entry. Some trials go further and require fresh tissue samples taken shortly before enrollment. This allows researchers to study the tumor’s genetic and molecular characteristics, which can help predict how it might respond to experimental treatments. These tissue samples may be analyzed for specific gene mutations, protein expression, or other markers that define which patients are most likely to benefit.^[5]^[9]

Blood tests are standard in clinical trial screening. Researchers need to know that a patient’s kidneys, liver, and bone marrow are functioning well enough to tolerate investigational drugs. Tests measuring complete blood counts, kidney function (creatinine levels), and liver enzymes are commonly required. Trials may exclude patients whose organ function falls below certain thresholds, as experimental treatments could be too risky in such cases.^[10]

Some trials focus on specific subgroups of patients. For instance, trials testing immunotherapy may require tests to measure immune system markers in the blood or tumor tissue. Trials for targeted therapies might require genetic testing to identify patients whose tumors have particular mutations. Understanding the biology of each patient’s cancer through these advanced diagnostics helps match individuals to the treatments most likely to help them.^[9]^[10]

Performance status assessment is another common requirement. This is a measure of how well a patient can carry out daily activities. Doctors use standardized scales to rate performance status, and many trials require patients to be relatively active and able to care for themselves. While not a laboratory test, this assessment is a form of diagnostic evaluation that helps ensure patients can safely participate in demanding treatment protocols.

Finally, clinical trials often require documentation of prior treatments. Detailed records of chemotherapy regimens, surgeries, and radiation therapy help researchers understand how much treatment a patient has already received and whether their disease has become resistant to standard therapies. This information is critical for trials testing new approaches in patients whose cancer has not responded to conventional treatment.^[10]^[13]

Finding and enrolling in a clinical trial can feel overwhelming, but specialized resources and patient navigators are available to help. Many cancer centers have coordinators who guide patients through the process, explain the required tests, and help gather necessary documentation. Organizations focused on osteosarcoma research also maintain databases of open trials and can assist families in identifying studies that might be a good match.

Prognosis and Survival Rate

Prognosis

The outlook for patients with metastatic osteosarcoma depends on several factors. The most important is whether doctors can completely remove all visible cancer—both the primary tumor and any metastases—through surgery. Patients who can undergo full surgical removal of their disease have the best chance of long-term survival. In contrast, patients whose metastases cannot be surgically removed face much greater challenges.^[5]^[10]

Where the cancer has spread also matters. Lung metastases are most common, and if there are only a few spots that can be removed surgically, outcomes may be better than if there are many scattered tumors or if cancer has spread to multiple organs. Bone metastases or metastases in soft tissues tend to be associated with poorer outcomes compared to isolated lung involvement.^[5]^[20]

The timing of metastasis is another factor. Patients who present with metastatic disease at the time of initial diagnosis have different outcomes than those who develop metastases months or years after treatment. Late-appearing metastases sometimes respond better to treatment than those present from the start.^[5]^[20]

How well the cancer responds to chemotherapy is critical. Doctors assess this by examining tumor tissue removed during surgery to see how much of the cancer cells have died in response to treatment given before surgery. Greater tumor cell death—called tumor necrosis—is associated with better prognosis. Unfortunately, metastatic osteosarcoma often shows resistance to standard chemotherapy, which is why researchers are working to find new treatment approaches.^[10]^[23]

A patient’s age and overall health also play a role. Younger patients sometimes tolerate intensive treatments better, though this does not guarantee better outcomes. What matters most is the ability to withstand aggressive therapy and surgery, which requires good organ function and physical resilience.

Survival Rate

Survival statistics for metastatic osteosarcoma are sobering but important to understand. When osteosarcoma has spread at the time of diagnosis, patients face a much harder battle than those with localized disease. Roughly 70% of patients who present with metastatic disease do not achieve cures with current treatments. This means that about 30% of patients with metastatic osteosarcoma at diagnosis may achieve long-term survival, typically those who can have complete surgical removal of all disease sites.^[9]^[10]

For comparison, patients who have localized osteosarcoma—cancer that has not spread—and receive modern treatment with chemotherapy and surgery have about a 70% chance of long-term survival. The presence of metastases dramatically changes these odds.^[9]^[10]

When osteosarcoma spreads to the lungs only and the metastases can be completely removed by surgery, survival rates improve compared to situations where complete removal is not possible. However, even with aggressive treatment, survival rates for metastatic osteosarcoma have not improved significantly over the past several decades. This lack of progress underscores the urgent need for new therapies and better understanding of how and why osteosarcoma spreads.^[10]^[13]

Two-year relapse-free survival rates vary widely depending on treatment and disease characteristics. Historical data from studies where patients did not receive chemotherapy showed that more than half developed metastases within six months, and about 90% had recurrent disease within two years. Modern chemotherapy has improved these outcomes, but metastatic disease remains extremely challenging.^[10]^[23]

It is important to remember that statistics describe large groups of patients and cannot predict what will happen to any individual person. Every patient’s situation is unique, and factors such as the biology of the tumor, response to treatment, and ability to undergo surgery all contribute to individual outcomes. Many patients and families find hope in clinical trials and emerging research aimed at improving survival for metastatic osteosarcoma.

#1 Clinical Trials Search in Europe